This infographic and the studies discussed were funded by AstraZeneca .
Can the perioperative approach in resectable G/GEJ adenocarcinoma be improved?
Surgery and perioperative FLOT are the primary treatment approach in locally advanced disease, but recurrence is common.
MATTERHORN, a global Phase III trial, evaluated perioperative durvalumab plus FLOT vs placebo plus FLOT.
This infographic reviews the trial design, survival outcomes, key subgroups, and surgical data.
This infographic and the studies discussed were funded by AstraZeneca . This content is intended for US Healthcare Professionals only.
Can the perioperative approach in resectable G/GEJ adenocarcinoma be improved? Surgery and perioperative FLOT are the primary treatment approach in locally advanced disease, but recurrence is common. MATTERHORN, a global Phase III trial, evaluated perioperative durvalumab plus FLOT vs placebo plus FLOT. This infographic reviews the trial design, survival outcomes, key subgroups, and surgical data.
You will learn:
